Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema

Diabetes

Volumn 64, Issue 10, 2015, Pages 3588-3599

  Kita, Takeshi ^a   Clermont, Allen C ^a   Murugesan, Nivetha ^a   Zhou, Qunfang ^a   Fujisawa, Kimihiko ^b   Ishibashi, Tatsuro ^b   Aiello, Lloyd Paul ^a   Feener, Edward P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN D; ARYLDIALKYLPHOSPHATASE 1; BEVACIZUMAB; BLOOD CLOTTING FACTOR 13; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT FACTOR H; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HAPTOGLOBIN; HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTER ALPHA TRYPSIN INHIBITOR; KALLIKREIN 1B; KININ; PLASMA KALLIKREIN; PREKALLIKREIN; PROTEOME; PROTHROMBIN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN; KALLIKREIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; KALLIKREIN KININ SYSTEM; KNOCKOUT MOUSE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RAT; RETINA MACULA HOLE; RETINAL THICKNESS; UPREGULATION; VITREOUS BODY; ANIMAL; BOVINE; CELL CULTURE; CHEMISTRY; COMPLICATION; DIABETES COMPLICATIONS; ENDOTHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; MACULAR EDEMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL;

ANIMALS; CATTLE; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; KININS; MACULAR EDEMA; MICE; RATS; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84982085630     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0317     Document Type: Article

References (48)

1. Yau JW, Rogers SL, Kawasaki R, et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564
2. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013;34:19-48
3. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-1239
5. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013;120:106-114
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
7. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-1696
8. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005;243:3-8
9. Simó R, Sundstrom JM, Antonetti DA. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 2014;37:893-899
10. Elman MJ, Aiello LP, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077, e35
11. Brown DM, Nguyen QD, Marcus DM, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022
12. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77
13. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-531
14. Clermont A, Chilcote TJ, Kita T, et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011;60:1590-1598
15. Pouliot M, Talbot S, Sénécal J, Dotigny F, Vaucher E, Couture R. Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PLoS One 2012;7:e33864
16. Abdouh M, Talbot S, Couture R, Hasséssian HM. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B (1) and B (2) receptors. Br J Pharmacol 2008;154:136-143
17. Catanzaro O, Labal E, Andornino A, Capponi JA, Di Martino I, Sirois P. Blockade of early and late retinal biochemical alterations associated with diabetes development by the selective bradykinin B1 receptor antagonist R-954. Peptides 2012;34:349-352
18. Liu J, Clermont AC, Gao BB, Feener EP. Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein. Invest Ophthalmol Vis Sci 2013;54:1086-1094
19. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007;13:181-188
20. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-1156
21. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-3218
22. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002;109:195-209
23. Ma JX, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res 1996;63:19-26
24. Liu J, Feener EP. Plasma kallikrein-kinin system and diabetic retinopathy. Biol Chem 2013;394:319-328
25. Feener EP. Plasma kallikrein and diabetic macular edema. Curr Diab Rep 2010;10:270-275
26. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 2008;7:2516-2525
27. Gao BB, Stuart L, Feener EP. Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol Cell Proteomics 2008;7:2399-2409
28. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57
29. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011;17:206-210
30. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001;42:789-794
31. Liu J, Gao BB, Feener EP. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome. Transl Stroke Res 2010;276-286
32. Kita T, Hata Y, Miura M, Kawahara S, Nakao S, Ishibashi T. Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes 2007;56:1421-1428
33. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006;47:3143-3150
34. Lowry JL, Brovkovych V, Zhang Y, Skidgel RA. Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium. J Biol Chem 2013;288:4174-4193
35. Li Q, Verma A, Han PY, et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci 2010;51:5240-5246
36. Nanjappa V, Thomas JK, Marimuthu A, et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res 2014;42:D959-D965
37. Farrah T, Deutsch EW, Omenn GS, et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011;10:M110.006353
38. Sonoda S, Sakamoto T, Shirasawa M, Yamashita T, Otsuka H, Terasaki H. Correlation between reflectivity of subretinal fluid in OCT images and concentration of intravitreal VEGF in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2013;54:5367-5374
39. Feener EP, Zhou Q, Fickweiler W. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost 2013;110:434-441
40. Bressler SB, Qin H, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012;130:1153-1161
41. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 2014;132:1309-1316
42. Sun JK, Radwan S, Soliman AZ, et al. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes. 29 January 2015 [Epub ahead of print]. DOI: 10.2337/db14-0782
43. Zheng L, Kern TS. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci (Landmark Ed) 2009;14:3974-3987
44. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007;48:5257-5265
45. Zheng L, Du Y, Miller C, et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007;50:1987-1996
46. Kim JH, Kim JH, Park JA, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006;39:339-345
47. Ni A, Chao L, Chao J. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 1998;273:2784-2791
48. Masuda T, Shimazawa M, Hara H. The kallikrein system in retinal damage/protection. Eur J Pharmacol 2015;749:161-163